Us Pharma
-
{
- All
- News
- Videos
-
Centre Asks States To Allocate More LPG To Key Industries Amid Iran Conflict
The Centre also asked states to communicate the new gas and petroleum distribution order to relevant departments.
-
Trump Imposes 100% Tariffs On Patented Drugs: Will It Impact India?
The bigger picture threatens a move away from established production hubs like India.
-
India-US Trade Deal Likely To Offer Tariff Relief On Exported Medicines
India's pharmaceutical industry has welcomed the interim trade agreement framework between India and the US, which offers tariff relief on medicines and several other Indian exports.
-
US Revives Drug Origin Debate, Cites Indian Exports
US renewed a push to require country-of-origin labeling on prescription drugs, citing temporary restrictions on pharmaceutical exports during the Covid pandemic by India as evidence that America's drug supply remains vulnerable to foreign disruptions
-
Indian Drugmakers Recall Medicines In The US Over Manufacturing Issues
Indian drugmakers Sun Pharmaceutical Industries and Cipla have recalled certain products from the US market due to manufacturing-related issues, according to the latest update from the US Food and Drug Administration (USFDA).
-
Hyderabad-Based Pharmaceutical Gets US Nod For Generic ADHD Drug: Why This Matters And What It Means
ADHD is a neurodevelopmental condition that affects both children and adults. It is characterised by symptoms such as difficulty concentrating, impulsive behaviour and hyperactivity.
-
How Trump's Policy For Prescription Drugs Could Reshape Trade With India
US President Donald Trump's announcement of sweeping prescription drug price cuts under a "Most Favoured Nation" policy has put India's pharmaceutical industry in focus.
-
Who Is Rama Raju Mantena? The Indian-American Pharma Titan Behind Viral Udaipur Wedding
Rama Raju Mantena is a prominent figure in the US pharmaceutical industry, serving as the Chairman and CEO of Ingenus Pharmaceuticals, a company with operations in the US, Switzerland, and India.
-
Trump May Exclude Generic Drugs From Tariffs. Good News For India?
The Donald Trump administration has dropped plans to impose tariffs on generic drugs from foreign countries, following months of debate over whether to impose taxes on the majority of medications prescribed in the US.
-
Countries And Companies Threatened By Trump's 100% Tariffs On Pharma
Donald Trump has shocked the global drug industry by announcing 100-percent tariffs on all branded, imported pharmaceutical products -- unless companies are building manufacturing plants in the United States.
-
EU Cites Trade Deal Immunity As Trump Hits Pharma With 100% Tariff
US President Donald Trump's announcement of steep new tariffs on medicines and other goods drew pushback from some allies on Friday, with the EU claiming immunity for its pharmaceutical industry under an earlier trade deal.
-
Why Trump's 100% Pharma Tariffs May Not Impact Indian Drugmakers Much
US President Donald Trump has said his administration will impose 100 per cent import tariffs on branded or patented pharmaceutical drugs from October 1, unless the pharma companies have or are building their manufacturing units in America.
-
Trump's 100% Tariff On Pharma Will Not Impact Generic Makers: Industry Leaders
Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines.
-
"No 100% Tariff On Pharma Import To US If...": What Donald Trump Said
Donald Trump on Thursday announced 100 per cent tariffs on pharmaceutical drugs, saying they will take effect on October 1.
-
Trump Declares 100% Tariff On Pharma Imports From October 1, India May Be Hit
US President Donald Trump has announced tariffs of up to 100 per cent on imports of branded and patented pharmaceutical products from October 1. India's pharmaceuticals sector, one of the most dependent domestic industries on trade with America.
-
Centre Asks States To Allocate More LPG To Key Industries Amid Iran Conflict
The Centre also asked states to communicate the new gas and petroleum distribution order to relevant departments.
-
Trump Imposes 100% Tariffs On Patented Drugs: Will It Impact India?
The bigger picture threatens a move away from established production hubs like India.
-
India-US Trade Deal Likely To Offer Tariff Relief On Exported Medicines
India's pharmaceutical industry has welcomed the interim trade agreement framework between India and the US, which offers tariff relief on medicines and several other Indian exports.
-
US Revives Drug Origin Debate, Cites Indian Exports
US renewed a push to require country-of-origin labeling on prescription drugs, citing temporary restrictions on pharmaceutical exports during the Covid pandemic by India as evidence that America's drug supply remains vulnerable to foreign disruptions
-
Indian Drugmakers Recall Medicines In The US Over Manufacturing Issues
Indian drugmakers Sun Pharmaceutical Industries and Cipla have recalled certain products from the US market due to manufacturing-related issues, according to the latest update from the US Food and Drug Administration (USFDA).
-
Hyderabad-Based Pharmaceutical Gets US Nod For Generic ADHD Drug: Why This Matters And What It Means
ADHD is a neurodevelopmental condition that affects both children and adults. It is characterised by symptoms such as difficulty concentrating, impulsive behaviour and hyperactivity.
-
How Trump's Policy For Prescription Drugs Could Reshape Trade With India
US President Donald Trump's announcement of sweeping prescription drug price cuts under a "Most Favoured Nation" policy has put India's pharmaceutical industry in focus.
-
Who Is Rama Raju Mantena? The Indian-American Pharma Titan Behind Viral Udaipur Wedding
Rama Raju Mantena is a prominent figure in the US pharmaceutical industry, serving as the Chairman and CEO of Ingenus Pharmaceuticals, a company with operations in the US, Switzerland, and India.
-
Trump May Exclude Generic Drugs From Tariffs. Good News For India?
The Donald Trump administration has dropped plans to impose tariffs on generic drugs from foreign countries, following months of debate over whether to impose taxes on the majority of medications prescribed in the US.
-
Countries And Companies Threatened By Trump's 100% Tariffs On Pharma
Donald Trump has shocked the global drug industry by announcing 100-percent tariffs on all branded, imported pharmaceutical products -- unless companies are building manufacturing plants in the United States.
-
EU Cites Trade Deal Immunity As Trump Hits Pharma With 100% Tariff
US President Donald Trump's announcement of steep new tariffs on medicines and other goods drew pushback from some allies on Friday, with the EU claiming immunity for its pharmaceutical industry under an earlier trade deal.
-
Why Trump's 100% Pharma Tariffs May Not Impact Indian Drugmakers Much
US President Donald Trump has said his administration will impose 100 per cent import tariffs on branded or patented pharmaceutical drugs from October 1, unless the pharma companies have or are building their manufacturing units in America.
-
Trump's 100% Tariff On Pharma Will Not Impact Generic Makers: Industry Leaders
Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines.
-
"No 100% Tariff On Pharma Import To US If...": What Donald Trump Said
Donald Trump on Thursday announced 100 per cent tariffs on pharmaceutical drugs, saying they will take effect on October 1.
-
Trump Declares 100% Tariff On Pharma Imports From October 1, India May Be Hit
US President Donald Trump has announced tariffs of up to 100 per cent on imports of branded and patented pharmaceutical products from October 1. India's pharmaceuticals sector, one of the most dependent domestic industries on trade with America.
